Popular Trials
Cancer Vaccine
DNA Vaccine for Chronic Hepatitis C
This trial studies the side effects and best dose of the DNA vaccine in treating patients with HCV infection. The vaccine may help the body build an effective immune response to kill cancer cells that express HCV infection.
Bcl-2 Inhibitor
Navitoclax + Sorafenib for Cancer
This trial is testing navitoclax and sorafenib tosylate in patients whose solid tumors have returned or don't respond to treatment. The drugs aim to stop cancer growth by blocking essential enzymes. Sorafenib has shown effectiveness in several cancers. The study will determine the best dose and monitor side effects.
Nucleos(t)ide Analogue
AB-729 + Pegylated Interferon for Chronic Hepatitis B
This trial is testing a new drug called AB-729 for patients with Chronic Hepatitis B. It is used along with existing treatments to lower virus levels, manage the virus, and boost the immune system.
Chemotherapy
MTL-CEBPA + Sorafenib for Liver Cancer
This trial is testing an experimental treatment (MTL-CEBPA) in combination with a standard of care treatment (sorafenib) in patients with advanced liver cancer (hepatocellular carcinoma) as a result of hepatitis B and/or C infection.
Popular Filters
Trials for Non-alcoholic Fatty Liver Disease Patients
Cardiac Glycoside
Digoxin for Alcoholic Hepatitis
This trial is testing whether a drug called digoxin is effective at treating people with severe alcohol-related liver damage. Patients will be given the drug or a placebo and monitored to see if their liver damage improves.
Glucagon-like peptide-1 receptor agonist
Semaglutide for Non-alcoholic Steatohepatitis
This trial is studying a medication called semaglutide in patients with NASH. Semaglutide is a well-known medication used to treat type 2 diabetes, and participants will either receive semaglutide or a dummy medication, with no way of knowing which they're getting. The study will last for 5 years, during which participants will have to inject themselves weekly and will have 21 clinic visits and 9 phone calls with clinical staff. Some of the clinic visits may last more than one day.
Trials for NAFLD Patients
Glucagon-like peptide-1 receptor agonist
Semaglutide for Non-alcoholic Steatohepatitis
This trial is studying a medication called semaglutide in patients with NASH. Semaglutide is a well-known medication used to treat type 2 diabetes, and participants will either receive semaglutide or a dummy medication, with no way of knowing which they're getting. The study will last for 5 years, during which participants will have to inject themselves weekly and will have 21 clinic visits and 9 phone calls with clinical staff. Some of the clinic visits may last more than one day.
Fibroblast Growth Factor 21 (FGF21) Analog
Efruxifermin for Nonalcoholic Steatohepatitis
This trial is testing a medication called efruxifermin to see if it can help people with a specific liver disease called NASH. The study focuses on patients whose disease has not yet progressed to cirrhosis. The medication works by reducing inflammation and fat in the liver to improve its health.
Phase 3 Trials
Monoclonal Antibodies
VAY736 for Advanced Cancer
This trial is testing a new medication called VAY736 to help adults with autoimmune hepatitis who haven't responded to or can't tolerate standard treatments. The goal is to see if VAY736 can reduce liver inflammation and improve liver function.
Nucleoside Reverse Transcriptase Inhibitor
Antiviral Therapy for Hepatitis B Transmission Prevention
This trial tests antiviral drugs to prevent hepatitis B transmission from mothers to babies. It focuses on high-risk pregnant women and their newborns in Africa. The drugs lower virus levels in mothers and protect babies until they are vaccinated. One of the drugs, Tenofovir disoproxil fumarate (TDF), has been studied for its ability to prevent the spread of hepatitis B from mothers to their babies.
Antiviral
HCV-Positive Organ Transplant Safety
This trial will test if it's safe to transplant organs from donors with HCV to recipients who don't have HCV. The recipient will take medication before and after the transplant. If successful, this could provide a large number of organs for transplant.
Trials With No Placebo
Hepatitis C Positive Liver Transplants for Liver Transplant Recipients
This trial is testing the safety and efficacy of transplanting livers from donors who are either positive or negative for the Hepatitis C virus. Treatment and prophylaxis will be administered to the recipients based on the donor's status.
Antiviral
Sofosbuvir/Velpatasvir for Kidney Transplant Recipients
This trial is testing the safety and efficacy of transplanting kidneys from donors who are either hepatitis C seropositive and non-viremic, or seropositive and viremic, to recipients who are seronegative. Treatment and prophylaxis will be administered using a transmission-triggered approach for the first scenario and a prophylaxis approach for the later scenario.
Direct Acting Antiviral Agent
Epclusa for Chronic Hepatitis C
This trial will study why some people still have liver complications after being cured of hepatitis C. Eligible participants will have different tests and some will take medication for 12 weeks. Then they will have follow-up visits for up to 10 years.
Sofosbuvir/Velpatasvir for Heart Transplant
This trial is testing the safety and efficacy of transplanting hearts from HCV seropositive non-viremic and HCV seropositive viremic donors to HCV seronegative recipients. Treatment and prophylaxis will be used to prevent HCV transmission.
View More Related Trials
Frequently Asked Questions
Introduction to autoimmune hepatitis
What are the top hospitals conducting autoimmune hepatitis research?
When it comes to advancing the understanding and treatment of autoimmune hepatitis, several top hospitals are leading the way. In Boston, Massachusetts General Hospital takes center stage with five active clinical trials focused on this condition. This renowned institution is no stranger to groundbreaking research and has been making strides in autoimmune hepatitis since recording its first trial in 2016. Meanwhile, in Cleveland, the prestigious Cleveland Clinic is also actively involved in five ongoing trials for autoimmune hepatitis. Although they have not conducted any previous specific trials for this condition, their expertise and commitment to research make them an important player in the field.
Another significant contributor to autoimmune hepatitis research is the National Institutes of Health Clinical Center located in Bethesda. With four active clinical trials currently underway, this esteemed institution plays a crucial role in advancing our knowledge of this complex disease. Similarly, at Washington University School of Medicine in Saint Louis, researchers are conducting four active clinical trials while having accomplished one all-time trial focusing on autoimmune hepatitis since their inaugural study began just a few years ago.
Rounding out the list is UPMC (University of Pittsburgh Medical Center) where three cutting-edge clinical trials targeting autoimmune hepatitis are currently taking place. While they haven't conducted any previous studies dedicated solely to this condition yet holding immense potential as a highly regarded medical center specializing across various fields.
These hospitals represent beacons of hope for individuals living with autoimmune hepatitis by providing access to innovative treatments and contributing invaluable data that will ultimately shape future care approaches globally
Which are the best cities for autoimmune hepatitis clinical trials?
When it comes to autoimmune hepatitis clinical trials, several cities emerge as leading hubs for research and development. New york City boasts 38 ongoing trials focusing on various treatments like DUR-928 30 mg and BNT162b2. Boston, Massachusetts follows closely behind with 25 active studies exploring interventions such as DUR-928 30 mg and Rozanolixizumab. Miami, Florida, Houston, Texas, and Los Angeles, California also show promise with their respective numbers of active trials. These cities provide individuals with autoimmune hepatitis access to cutting-edge research opportunities that pave the way for improved treatment options and better outcomes in the future.
Which are the top treatments for autoimmune hepatitis being explored in clinical trials?
Autoimmune hepatitis is a complex condition, but researchers are actively exploring various treatments through clinical trials. Among the top contenders are:
- Rituximab: 5 active trials, 93 all-time autoimmune hepatitis trials, first listed in 1997
- Tofacitinib: 3 active trials, 36 all-time autoimmune hepatitis trials, first listed in 2011
- Mycophenolate mofetil: 2 active trials for autoimmune hepatitis, involved in a total of 65 clinical studies since its introduction in the year2000.
What are the most recent clinical trials for autoimmune hepatitis?
Recent clinical trials have brought hope to individuals battling autoimmune hepatitis, as researchers explore new treatment options. One such trial focuses on the depletion of CD3/CD19 in an autologous stem cell transplant for autoimmune hepatitis. By targeting specific cells involved in the immune response, this approach aims to restore balance and alleviate symptoms. Another study examines the efficacy of HepB mAb19 administered intravenously for autoimmune hepatitis, evaluating its potential benefits in managing the condition. Additionally, Panzyga IVIG is being investigated as a potential therapy option, exploring its ability to modulate the immune system and improve liver function in patients with autoimmune hepatitis. These ongoing trials pave the way towards improved treatments that may enhance outcomes for those affected by this challenging condition.
What autoimmune hepatitis clinical trials were recently completed?
Recently completed clinical trials for autoimmune hepatitis have brought promising advancements in the field. Notably, a trial sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases investigated the efficacy of budesonide treatment, concluding in March 2021. Another significant milestone was reached when a trial exploring mycophenolate mofetil as a potential therapy was completed in January 2021. The completion of these trials underscores ongoing efforts to find effective treatments for autoimmune hepatitis and offers hope to patients affected by this challenging condition.